読み込み中
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
前日終値
$6.90
−$0.01 · -0.14%
日中の時刻はETです。市場データは遅延する場合があります。
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
日中レンジ
現在 $6.90
52週レンジ
現在 $6.90
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
66
割安
センチメント
43
まちまち
リスク
45
やや高いリスク
モメンタム
50
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
日中レンジ
現在 $6.90
52週レンジ
現在 $6.90
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1637.98万 USD | 1016.72万 USD | 719.9万 USD | 668.1万 USD | 687.3万 USD |
| 売上原価 | 478.74万 USD | 346.81万 USD | 281.7万 USD | 366万 USD | 392.1万 USD |
| 粗利益 | 1159.24万 USD | 669.91万 USD | 438.2万 USD | 302.1万 USD | 295.2万 USD |
| 研究開発 | 2095.65万 USD | 1615.04万 USD | 1437.7万 USD | 1469万 USD | 1527.7万 USD |
| 販売・一般管理 | 3261.21万 USD | 2202.33万 USD | 1862.1万 USD | 1793.3万 USD | 1796.6万 USD |
| 営業費用 | 5356.86万 USD | 3817.37万 USD | 3299.8万 USD | 3514.7万 USD | 3324.3万 USD |
| 受取利息 | 108.87万 USD | 136.71万 USD | 164.2万 USD | 104.97万 USD | 20.32万 USD |
| 支払利息 | — | — | 77万 USD | 16.71万 USD | 6.64万 USD |
| 減価償却費と償却費 | 56.98万 USD | 93.6万 USD | 92.9万 USD | 160.4万 USD | 187.9万 USD |
| 営業利益 | −4197.62万 USD | −3147.46万 USD | −2861.6万 USD | −3212.6万 USD | −3029.1万 USD |
| 純利益 | −4331.52万 USD | −2648.05万 USD | −2856.9万 USD | −2866.9万 USD | −3069.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.00
上昇余地（59.42%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年10月16日 | 1:10 | — | — |
発効済み 2019年10月16日
1:10
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
